Fidelity Select Biotechnology Portfolio (FBIOX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
FBIOX Chart
People also search for
Fidelity Select Biotechnology Portfolio Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CGL Chester Gary Lloyd Coston, McIsaac & Partners | 73 | $1,203.31 | $1,789.23 | $585.92 | 48.69% |
Fidelity Select Biotechnology Portfolio (FBIOX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fidelity Select Biotechnology Portfolio ever had a stock split?
Fidelity Select Biotechnology Portfolio Profile
| NASDAQ (NMS) Exchange | US Country |
Overview
This fund is designed for investors aiming to capitalize on companies with above-average growth potential, commonly referred to as "growth stocks". By focusing on both domestic and foreign issuers, the fund offers a broad exposure to various markets. The investment decisions are rooted in thorough fundamental analysis, considering aspects such as financial health, industry standing, and broader market and economic indicators. Despite its ambition to invest in growth-centric companies, the fund remains non-diversified, indicating a potentially higher risk and reward profile due to its concentrated investment approach.
Products and Services
- Investment in Common Stocks:
- Domestic and Foreign Issuers:
- Non-Diversified Portfolio:
The fund primarily invests in common stocks of companies, which are believed to possess above-average growth potential. These investments span across a wide range of sectors and geographical locations, providing an opportunity for diversified exposure to growth-oriented equities.
A distinctive feature of this fund is its investment in both domestic and international companies. This allows investors to benefit from growth opportunities not just in their home country but globally, thereby diversifying their investment risks and potential returns across different markets and economies.
The non-diversified status of the fund means it may invest more heavily in fewer securities. While this approach can lead to higher volatility and risk, it also opens the door for potentially greater returns by allowing the fund to take significant positions in companies that exhibit strong growth prospects.
